A.O. Ospedale Papa Giovanni XXIII Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2014
NCT02260375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ANNA FALANGA | ASST Papa Giovanni XXIII, Bergamo

Active Ingredients

Drugs in Phase 2 Trials (3)

hydroxychloroquine (plaquenil) (1 trial)

lisinopril (zestril) (1 trial)

tofacitinib (xeljanz) (1 trial)

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis (Phase 2)

Kidney Failure, Chronic (Phase 1)

Lung Diseases, Interstitial (Phase 2)

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4